ArticleDiabetes therapy : research, treatment and education of diabetes and related disorders2026
Real-World Cohort Study of Semaglutide in Adults with Type 2 Diabetes Using an Electronic Health Records Database in Tianjin, China.
Article in Diabetes therapy : research, treatment and education of diabetes and related disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT06351748. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Real-world Study of CHina Ozempic cLinicAl pRactice in Patients With Type 2 Diabetes (SCHOLAR)
Open the trial in the graphWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe aim of this study was to evaluate changes in clinical parameters among adults with type 2 diabetes (T2D) after initiating subcutaneous semaglutide in Chinese clinical practice.
methodsSCHOLAR was a retrospective cohort study using data from the Tianjin regional electronic health records database, including adults with T2D who initiated once-weekly semaglutide (full analysis set [FAS]). Endpoints included change in glycated hemoglobin (HbA
resultsAmong 26,859 individuals (FAS), mean ± SD age was 57 ± 13 years, and duration of T2D was 4 ± 3 years. Individuals with HbA
conclusionsInitiating once-weekly semaglutide was associated with significant improvements versus baseline in glycemic control and lipids in people with T2D from Tianjin, China. Safety of semaglutide was similar to the established safety profile per adverse events assessment. CLINICAL TRIALS REGISTRATION: NCT06351748.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.